Clinical Trial

Disease: Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)

Disease info:

Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion.  This includes:

Oesophageal Cancer
Liver Cancer
Stomach Cancer
Gallbladder & Biliary Tract Cancer
Pancreatic Cancer
Gastro-Intestinal Stromal Tumour (GIST)
Neuroendocrine Tumours (NETs)
Colorectal Cancer
Small Bowel Cancer
Anal Cancer

Gastric (stomach) cancer is the fourth most common cancer worldwide. It begins in the stomach lining and can spread to lymph nodes or other organs. Most cases are adenocarcinomas, though rarer forms include gastrointestinal stromal tumours, carcinoid tumours, and lymphomas.

A key risk factor is infection with Helicobacter pylori, which can cause inflammation and ulcers. Other risks include a family history of stomach cancer, certain inherited genetic syndromes, smoking, heavy alcohol use, obesity, a high-salt diet, and exposure to industrial chemicals. Men and people of African American, Hispanic, or Asian descent face higher risk.

Early stages often produce few or no symptoms. When present, warning signs may include difficulty swallowing, stomach pain or discomfort, bloating after small meals, nausea or vomiting (sometimes with blood), blood in the stool, and unexplained weight loss. Because these symptoms can mimic common digestive issues, medical evaluation is important for accurate diagnosis.

Colorectal cancers form when malignant cells grow in the colon or the rectum. Because GI cancers and colorectal cancers are closely related, they make up a distinct family of cancers.

Source: Gastric (Stomach) Cancer Symptoms & Stages | UPMC

 

Frequency:
Approximately 8,000 carcinoid cancers that start in the gastrointestinal tract are diagnosed each year in the United States.
Official title:
Exploratory Study of NK510 Cell Therapy in the Treatment of Recurrent and Refractory Advanced Gastric Cancer and Colorectal Cancer
Who:
Sponsor:

Base Therapeutics (Shanghai) Co., Ltd.
 

Partners:
Locations:

Jiangsu, China

Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University, Nanjing, Jiangsu, China

Study start:
Nov. 1, 2025
Enrollment:
15
Gene editing method:
AccuBase® base editor
Type of edit:
Gene knockout and gene knock in
Gene:
Knockout of PD-1 and knock in of CD16
Delivery method:
- Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Not yet recruiting

Description

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer. NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.

Last updated: Sep. 22, 2025
close
Search CRISPR Medicine